Triple Negative Locally Advanced Non-resectable Breast Cancer Clinical Trials in San Antonio, Texas

A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors